Valid until Jun. 30, 2025 Primary Responsibilities: 1. Responsible for the overall planning of clinical research, including the investigation of clinical trial progress and relevant information of similar varieties at home and abroad, clinical evaluation and feasibility analysis, and the formulation of clinical development strat
Learn MoreNEWS
-
Following its prior receipt of FDA Breakthrough Therapy Designation (BTD) for the treatment of Primary Biliary Cholangitis (PBC), the self-developed Class 1 new drug CS0159 oral tablet from Cascade has now also received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) f
-
July 24, 2025, Shanghai – Cascade announced that its self-developed Class 1 new drug, the CS0159 oral tablet, has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA). Based on CS0159's outstanding clinical potential in treating Primary Biliary Cholan
